Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

AstraZeneca shares rocket as Pfizer confirms takeover bid

AstraZeneca shares rocket as Pfizer confirms takeover bid

Shares in AstraZeneca (AZN.L) have rocketed after US rival Pfizer confirmed it had made a tentative £58.8 billion bid for the pharmaceutical business.

AstraZeneca surged by £5.94, or 14.6%, to £46.74 as Pfizer confirmed reports that first featured in the Sunday Times that it had approached AstraZeneca over a takeover, only to be rebuffed. It added that it had made a fresh approach last week seeking to renew discussions, only to receive a further rejection. The jump in Astra shares has helped to drag the FTSE 100 27 points, or 0.4%, higher, at 6,712. 

‘Pfizer confirms that it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction. After limited high-level discussions, AstraZeneca decline to pursue negotiations,’ Pfizer said in a statement to the market.

‘In light of recent market developments, Pfizer contacted AstraZeneca on 26 April 2014 seeking to renew discussions in order to develop a proposal that could be recommended by both companies to their shareholders. AstraZeneca again declined to engage. Pfizer is currently considering its options with respect to AstraZeneca,’ it added.

Pfizer said its offer had valued AstraZeneca at £46.61 a share, a 30% premium to its £35.86 price on 3 January. Shares have now risen above that as investors anticipate a firm bid from Pfizer.

Pfizer has said any future bid would be based on the undisturbed price on 17 April, before news of its approach broke, prompting a jump of over 7% in Astra shares. A 30% premium on that price would value Astra at £49.15 per share.

Liberum analyst Naresh Chouhan said a deal at that price would be unlikely because AstraZeneca would be ‘unwilling to accept' and Pfizer would ‘not want to go hostile’ and suggested a price closer to £60 would offer good value for Astra shareholders.  Analysts at Barclays said Pfizer could make a bid of up £56 per share before the price began to offset any earnings boost.

BG Group (BG.L) was the biggest faller, dropping 34p, or 3%, to £11.12 as the oil and gas group announced the shock departure of boss Chris Finlayson due to personal reasons, and issued disappointing new guidance over 2014 production figures.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Biotech Growth: we will ride out this storm

Biotech Growth: we will ride out this storm

Geoffrey Hsu of Biotech Growth Trust says the sell-off in biotechnology stocks represents a buying opportunity for long-term investors.

Play Sector Spotlight: Kleinwort Benson's Choukeir on UK equities

Sector Spotlight: Kleinwort Benson's Choukeir on UK equities

In our first Sector Spotlight of the year we explore UK equities on the back of the extreme market turbulence in 2016.

Play Picton: the UK property hotspots for rental income

Picton: the UK property hotspots for rental income

Picton Property Income CEO Michael Morris reveals how he is planning to ride the ‘ripple effect’ as UK economic growth spills out from the capital across the country.

Your Business: Cover Star Club

Profile: PortfolioMetrix is on a mission to kill 'Frankenstein' systems

Profile: PortfolioMetrix is on a mission to kill 'Frankenstein' systems

In a buyers’ market for off-the-peg discretionary management, self-funded start-ups begin at an inherent disadvantage

Wealth Manager on Twitter